Summary We have shown previously that it is possible to target complement-mediated killing against cultured ovarian tumour cells in vitro. As malignant ovarian cells usually grow in solid nodules in vivo, we have in the present study examined the effectiveness of complement killing against ovarian teratocarcinoma cells (PA-1) growing in three-dimensional tumour microspheroids (TMSs). Our study shows that PA-1 cells growing in TMSs are less susceptible to complement-mediated killing than cells growing in monolayer cultures, even after neutralization of protectin (CD59), the main inhibitor of complement lysis. Cells in suspension and cells growing in TMSs showed a similar expression of membrane co-factor protein (MCP, CD46) and CD59. Decay-accelerating factor (DAF, CD55) was not detected on the surface of cells in suspension, but appeared focally on the outermost cell layers of the TMSs. Complement-activating antibodies bound to all PA-1 cells in suspension but only to the most peripherally located cells in TMSs, even though the target antigens were similarly expressed in the two systems. Antibody-induced complement activation on PA-1 cells in suspension led to C3 and C5b-9 deposition on most cells, while C3 and C5b-9 were only found on the outermost layers of the TMSs. The increased complement resistance of tumour cells growing in threedimensional spheroids is partly because of an insufficient penetration of antibodies and complement into the TMSs. TMSs are a useful model for the development of more efficient ways to kill malignant cells in micrometastases with monoclonal antibodies and complement.
Nucleated cells, and tumour cells in particular, are resistant to complement (C)-mediated killing (Vogel, 1991) . The resistance is to a great extent mediated by C-regulatory proteins and cell membrane repair mechanisms (Morgan and Meri, 1994) . The C-regulatory proteins act at critical steps in the C pathways. They interfere during the C3/C5 convertase stage or restrict formation of the terminal cytolytic membrane attack complex (MAC) (Morgan and Meri, 1994) . Decay-accelerating factor (DAF, CD55) (Nicholson-Weller et al, 1982; Pangburn et al, 1983) and complement receptor 1 (CR1, CD35) (Fearon, 1979) directly inhibit the formation and promote decay of the C3/C5 convertases of both classical and alternative pathways. CR1 (Fearon, 1979) and membrane co-factor protein (MCP, CD46) (Seya et al, 1986 ) act indirectly by serving as cofactors for the enzymatic degradation of C3b or C4b. Homologous restriction factor (HRF) (Zalman et al, 1986) or C8 binding protein (C8bp) (Schonermark et al, 1986 ) and protectin (CD59) (Sugita et al, 1988) regulate the formation and function of MAC. While HRF/C8bp awaits detailed molecular characterization, the processed cell surface form of CD59 is known to have 77 amino acids (Fletcher et al, 1993) linked to the cell membrane via a glycosyl-phosphatidylinositol (GPI) anchor (Stefanova' et al, 1989) . CD59 inhibits C lysis by interacting with C8 and C9 in the nascent MAC and thereby restricting the number and polymerization of C9 molecules in the complex (Meri et al, 1990; Rollins and Sims, 1990) . By preventing membrane insertion of C9 molecules, CD59 effectively blocks the formation of ion-permeable transmembrane channels on the surface of human cells (Meri et al, 1990) .
We have recently observed that the C regulators MCP, DAF and CD59 are expressed on ovarian carcinoma cells in vivo and in vitro, and that DAF and CD59 appear to be the main factors in protecting malignant ovarian cells against C-mediated killing (Bj0rge et al, 1996) . As a tumour arising from a 'non-essential' organ that remains primarily confined to the peritoneal cavity, ovarian cancer is particularly well suited for monoclonal antibody (MAb) adjuvant immunotherapy (Rubin, 1993) . Numerous clinical antibody treatment trials have, unfortunately, failed to lead to any consistent pattern of clinical response (Hamilton et al, 1987; Goodman et al, 1990; Guadagni et al, 1993; Rubin, 1993) . Consequently, the cells' ability to resist C attack may at least partly explain the lack of therapeutic efficiency of tumour-specific MAbs (Bj0rge et al, 1996) . If ovarian malignant cells are to be killed by tumour-specific MAbs and C, the selected MAbs have to be efficient activators of C and the cells' resistance to C has to be overcome.
Most in vitro studies on the expression and function of C regulators on malignant cells have used cell suspensions and/or monolayer cell cultures (Cheung et al, 1988; Bj0rge et al, 1994; Hakulinen and Meri, 1994; Junnikkala et al, 1994; Brasoveanu et al, 1995; Maenpaa et al, 1996) . In many respects, these systems are markedly different from the actual conditions in solid tumours in vivo (Miiller-Klieser, 1987) . As the vulnerability of cells to C depends on their interaction with the microenvironment, the properties and functions of C-regulatory mechanisms in three-dimensional systems may differ from those observed in two-dimensional systems.
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Tumour cell microspheroids (TMSs) are widely used in in vitro models of tumour nodules (Sutherland, 1988; Carlsson and Nederman, 1992) . Like tumour cells in vivo, cells in these spherical aggregates are exposed to gradients of pH, pO2 and nutrients. TMSs are considered to provide a system of compact cells in a cellular microenvironment resembling that found in vivo. In this study, we examined the expression and function of C regulators in ovarian TMSs to develop an in vitro model for analysing the effects of targeted C attack against three-dimensional ovarian tumours.
MATERIALS AND METHODS Antibodies and sera
The rat hybridoma cell line producing the YTH53.1 anti-CD59 monoclonal antibody (MAb) was kindly provided by Professor H Waldmann (Sir William Dunn School of Pathology, University of Oxford, UK). YTH53.1 (IgG2b) was purified from cell culture supernatants using a Protein G Sepharose 4 Fast Flow affinity column (Pharmacia, Uppsala, Sweden). The MAb YTH53.1 was biotinylated by cross-linking biotin to the £-amino groups via a long arm N-hydroxylsuccinimide ester using the biotin labelling method of Vector Laboratories (Burlingame, CA, USA) essentially as described (Jokiranta and Meri, 1993) . Lack of activation of the classical C pathway was examined using a Clq binding test (Jokiranta and Meri, 1993) . The mouse MAb BRIC230 (IgGI) (anti-DAF) was a generous gift from the International Blood Group Reference Laboratory (Bristol, UK). The mouse MAbs BRIC229 (IgG2b) (anti-CD59), J4-48 (IgGI) (anti-MCP) and aEll (IgG2a) (anti-C5b-9) were purchased from Bioproducts Laboratories (Elstree, UK), Serotec (Oxford, UK) and Dakopatts (Glostrup, Denmark) respectively. A fluorescein isothiocyanate (FITC)-conjugated goat anti-C3c MAb was purchased from Nordic Immunological Laboratories (Tilburg, The Netherlands). The polyclonal antibody S2 was raised by immunizing a rabbit three times intramuscularly with 107 heat-killed MCF7 cells (breast adenocarcinoma cells) . When appropriate, IgG fractions were prepared by protein G affinity chromatography (Pharmacia). Normal human serum (NHS) was separated from coagulated blood samples from healthy laboratory personnel, divided into 2-ml aliquots and stored at -70°C until used.
Cell culture
The ovarian teratocarcinoma cell line PA-1 was obtained from American Type Culture Collection (ATCC, Rockville, MD, USA). The cells were grown in monolayers at 37°C in a humidified atmosphere of 5% carbon dioxide in Dulbecco's modified Eagle medium (DMEM; Gibco, Paisley, UK), supplemented with 10% heat-inactivated fetal calf serum (FCS; Gibco), 2 mM L-glutamine (Nord Cell, Bromma, Sweden) and antibiotics [10 units ml-1 of penicillin (AL, Oslo, Norway) and 100 jg ml-1 of streptomycin (Glaxo, UK)]. Cells were grown in cell culture flasks (Costar, MA, USA) or on coverslips in chambers. Cells were detached from the culture flasks with Versene/EDTA (Gibco), washed twice and resuspended in phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA; Sigma).
Tumour microspheroids (TMSs) TMSs of PA-I cells were initiated by seeding cells on 24-well plates (Costar) coated with a thin layer of agarose [0.5% Agarose M (Pharmacia) in distilled water]. PA-1 cells placed into growth medium attached to one another and formed spherical cell aggregates. Cell viability was regularly assessed by microscopic examination after incubation with propidium iodide (Sigma). PA-I spheroids were grown for an average of 2 weeks and the spheroids with diameters between 100-150 jim were selected for the experiments. Some of the TMSs were harvested, washed and snap frozen in isopentane precooled with liquid nitrogen for immunohistochemical analysis. Fresh TMSs were used for the functional studies.
Initially, we also tried to make spheroids of the ovarian carcinoma cell lines SK-OV-3, Caov-3 and SW626 (ATCC), but their ability to form spheroids was poor. Immunofluorescence microscopy Cryostat sections of TMSs (5 jim) on gelatin-coated slides were fixed in acetone at -20°C for 5 min. After fixation, the sections were incubated with the MAbs BRIC229, (1 jig ml-') or with S2 (dilution 1:100) in a moist chamber according to the immunofluorescence labelling protocol described above. After the final washes in PBS/BSA, the sections were mounted in Mowiol (Heimer and Taylor, 1974) . A Leitz microscope (Heidelberg, Germany) equipped with standard fluorescein optics was used for the immunofluorescence analysis.
Flow cytometry analysis (FCM)
PA-1 cells grown on coverslips were stained similarly, except that in the standard assay the specimens were not fixed in acetone before the staining procedure.
Penetration of antibodies into TMSs
TMSs on agarose-coated plates were incubated with 10 jig ml-' of BRIC229 or heat-inactivated S2 (dilution 1:50) in growth medium for 18 h at 37°C in a humidified atmosphere with 5% carbon dioxide. A mouse monoclonal antibody with no known reactivity with the PA-I cells and normal rabbit serum were used as controls.
After washing (2 x 30 min, 37°C) in PBS, the TMSs were incubated for another 18 h with the FITC-conjugated F(ab')2 rabbit anti-mouse Ig (Dakopatts) or FITC-conjugated F(ab')2 donkey anti-rabbit Ig (Jackson Immunoresearch Laboratories, PA, USA).
British Journal of Cancer (1997) 75(9), [1247] [1248] [1249] [1250] [1251] [1252] [1253] [1254] [1255] Complement regulators and ovarian teratocarcinoma microspheroids 1249 After washing, the TMSs were fixed in 1% paraformaldehyde for 2 h and analysed on a BioRad MRC 1000 confocal laser scanning microscope, CLSM (Bio-Test, Rygge, Norway) with a crypton-argon laser. TMSs were scanned in a plane 50-100 jm into the spheroid using the 488 nm excitation line. Alternatively, the fixed TMSs were snap frozen, sectioned and examined in a Leitz immunofluorescence microscope.
Deposition of C3 and C5b-9 on PA-1 cells after C activation PA-l cells (2 x I0) in suspension were incubated for 1 h on ice in 10% heat-inactivated S2 diluted in PBS/BSA. After washing twice in Veronal-buffered saline, pH 7.4 (VBS), the PA-1 cells were further incubated with 100 jl of 10% NHS diluted in VBS for 30 min at 37°C. In controls, the classical and alternative C pathways were blocked by adding 0.01 M EDTA to the reaction mixture. After washing three times in PBS/BSA, the cells were immunostained with the anti-C5b-9 MAb aEl 1 (2 jig ml-') or with the FITC-conjugated goat anti-human C3c (diluted 1:40) and processed for FCM as described above. Negative controls included unsensitized cells incubated with NHS. TMSs were examined in a similar fashion, except that the TMSs were incubated for 18 h with S2 during the sensitization step and that C depositions were analysed by immunofluorescence staining of cryostat sections of TMSs.
C-mediated lysis of PA-1 cells Washed TMSs grown for 2 weeks were labelled with 100 jCi "1chromium (51Cr; Na51CrO4; Amersham, UK) (approximately 500
TMSs in 1 ml of DMEM) for 12 h at 370C, with occasional shaking. This incubation time has earlier been shown to lead to efficient uptake of 5'Cr into the TMSs (Jaaskelainen et al, 1989 200 ul) for 30 min at 370C. After centrifugation (500 g for 5 min), 100 pl samples of the supernatants were carefully removed and counted in a gammacounter. 5'Cr-release in the absence of antibodies was taken as a background (range: 0.5-1.0% of total label incorporated) and release by 0.1% Nonidet P40 (BDH Laboratories Supplies, Poole, UK) as total release of radioactivity. During a 30-min incubation, 0.1% NP40 released 8% of total 51Cr incorporated. Cell lysis in the TMSs was determined as percentage of antibody plus complement-induced 51Cr release into the supernatant. Examination of C-mediated lysis of PA-1 cells in suspension was performed in a 5tCr-release assay as described earlier . A total of 5 x 107 cells were labelled with 25 ,uCi of 51Cr in 150 1l of DMEM. After washes and a 30-min reincubation to release loosely bound 51Cr, the cells were aliquoted (105 cells per tube) for the 5'Cr-release assay, which was performed in a similar way to that described for TMSs above.
RESULTS

Spheroid formation and growth
Aggregates of PA-I cells were observed as early as 2-3 days after seeding on agar gels. Large spheroids of densely packed cells with a regular round shape were formed at the end of the first week. The viability of the cells within the spheroids was repeatedly checked by staining with propidium iodide, which showed that only a few nuclei, if any, outside a central core adsorbed the dye. _s-_- Figure 3 Confocal microscopy analysis of binding of antibodies to the TMSs. TMSs were cultured on agar-coated plates in the presence of the anti-CD59 MAb BRIC229 (A) or the polyclonal rabbit antibody S2 (C) (18 h, 37°C) followed by FlTC-conjugated rabbit anti-mouse 19 or FlTC-conjugated donkey anti-rabbit 19 (18 h, 37°C). TMSs were fixed in paraformaldehyde (1%, 2 h) and analysed by confocal laser scanning microscopy. Controls were cultured with an unrelated mouse MAb (B) or normal rabbit serum (D) in the first step. BRIC229 bound to the outermost 4 or 5 cell layers (A), whereas S2 bound very strongly to the outer 7 or 8 cell layers, more weakly to the next 2 or 3 cell layers and not to the most centrally located cells (C)
FCM was used to further analyse the expression of complement regulatory proteins on the surface PA-1 cells in suspension. These experiments showed that CD59 and MCP were expressed on the surface of the cells. The widths of the unimodal fluorescence profiles for both molecules were narrow, and more than 90% of the cells were stained. The cells were not, or only very weakly, stained with the anti-DAF MAb BRIC230 (Figure 2 Binding of the polyclonal S2 antibody to PA-1 cells and spheroids Figure 3A) . After exposure of the TMSs to S2 as many as 7 or 8 outer cell layers showed a strong positive staining. The next 2 or 3 more centrally located cell layers showed a weaker staining, thereby constituting a transition zone. The most centrally located cells were not stained ( Figure 3C ).
These findings were confirmed by immunofluorescence microscopy of cryostat sections of TMSs subjected to the same penetration experiments (data not shown). Control TMSs incubated with an irrelevant MAb or normal rabbit serum during the first incubation step showed no ( Figure 3B ) or weak, non-specific ( Figure 3D ) staining.
British Journal of Cancer (1997) 75(9), [1247] [1248] [1249] [1250] [1251] [1252] [1253] [1254] [1255] . Complement regulators and ovarian teratocarcinoma microspheroids 1253 tested tumour antigen-reactive mouse MAbs (Bj0rge et al, 1996) activated C on the surface of PA-I cells. To see if C components could penetrate into spheroids, fresh TMSs were sensitized with S2 for 18 h and thereafter treated with NHS (30 min, 37°C). Cryostat sections of the spheroids stained positive for both C3c and C5b-9. The staining patterns were similar and, interestingly, only the outer 2-5 layers were stained ( Figure 5 ). No binding of the anti-C3c or anti-C5b-9 MAb was seen to cells in suspension or to TMSs that were not sensitized with the S2 antibody. The presence of EDTA in the incubation mixture also prevented C3c and C5b-9 deposition on S2-sensitized cells and spheroids.
Sensitivity of PA-1 cells and spheroids to C-mediated cytotoxicity
The cytotoxic effect of human C and the functional significance of CD59 in protecting PA-1 cells against C-mediated damage was examined using cells in suspension and in TMSs. PA-1 cells in suspension sensitized with the polyclonal rabbit antibody S2 showed a dose-dependent vulnerability to C-mediated lysis ( Figure  0 . 3 6A). Using a saturating concentration of S2, approximately 65% of the cells were killed in the presence of 25% NHS during a 30-min incubation at 37°C. Ten per cent NHS resulted in the killing of 17% of target cells. In the presence of 25% NHS and 25 gg ml-l of the biotinylated anti-CD59 YTH53.1, an average of 88% of PA-1 cells were killed. In comparison, PA-I cells in TMSs were found to be resistant to C-mediated cytotoxicity ( Figure 6B ). After sensitization with S2, in the presence of 25% NHS for 30 min, approximately 4% of the cells in the TMSs were lysed, while 8% of the cells in the spheroids were lysed when the biotinylated YTH53.1 MAb was added to the reaction mixture (release of 51Cr by 0.1% NP40 was taken as total lysis). In the absence of the sensitizing rabbit antibody, no lysis occurred in the two cell systems with the combination of biotinylated YTH53.1 MAb and NHS. After activation of the classical pathway of C (10% serum) by S2, C3 and CSb-9 were detected on more than 95% and 60% of the PA-1 cells in suspension respectively (Figure 4) . None of the The experiments described in this paper demonstrate that cells in suspension and cells growing in multicellular spheroids differ in their ability to resist C-mediated cytotoxicity. Cells growing in TMSs were much more difficult to kill by C than cells in suspension. This phenomenon was at least partly dependent on differences in the binding of C-activating antibodies to cells in the two systems and possibly on acquisition of an increase in C resistance when the tumour cells are grown in TMSs.
In line with our recent study, we found MCP and CD59 expression, but no or only negligible DAF expression, on PA-1 cells in suspension and on cells growing in monolayers (Bj0rge et al, 1996) . Similarly, PA-I cells growing in TMSs also expressed MCP and CD59, and the intensity of expression was homogeneous throughout the TMSs. Interestingly, DAF was also expressed on the PA-1 TMSs. The location of DAF-expressing cells was rather distinct, as only foci in the outer layers in the TMSs expressed DAF. Differences between spheroids and monolayers in the expression of integrins (Brackman, 1995) , extracellular matrix components (Brackman, 1995) , growth factors (Ness et al, 1994) and growth factor receptors (Ness et al, 1994) have been observed earlier. A possible explanation for these differences is the influence of the distinct cellular microenvironment present in the spheroids (Sutherland, 1988; Carlsson and Nederman, 1992) . PA-1 is a British Journal of Cancer (1997) teratocarcinoma cell line that can differentiate into different germ cell layers when growing on non-adhesive surfaces (Zeuthen et al, 1980) . On their surface, the cell aggregates contain endoderm-like cells that surround the inner cell mass. As DAF is a marker of early differentiation (Holmes et al, 1992) , the induction of its expression could alternatively be explained by the differential organization of cells in the TMSs. Although both S2 and BRIC229 stained sections of TMSs homogeneously, confocal microscopy showed that these antibodies had only a limited ability to penetrate into live spheroids. These findings were confirmed by ordinary immunofluorescence microscopy on cryostat sections to exclude experimental caveats inherent in the staining protocol used for the confocal laser scanning microscopy analysis. The S2 rabbit IgG penetrated deeper into the spheroids than BRIC229. As it has been predicted that low-affinity antibodies penetrate into tumours more readily than high-affinity antibodies (Fujimori et al, 1989; Langmuir et al, 1992) , the difference between BRIC229 and S2 is probably because BRIC229 is a high-affinity MAb (Fletcher et al, 1992) , while the S2 IgG probably contains antibodies with different affinities against different antigens. Lack of antibody penetration into the core of TMSs probably reflects the existence of tight intercellular junctions between the cells (Jain, 1988) . In addition, cells in the spheroids may have synthesized a glycocalyx (Riethmuller et al, 1993) or a basement membrane-like structure (Zeuthen et al, 1980 ) that also restrict the access of antibodies into the deeper layers of the TMSs.
Antibody-mediated C activation on PA-1 cells in suspension induced C deposition on nearly all the cells. A similar C attack on the PA-1 TMSs resulted only in deposition of C factors on the outer cell layers of the aggregates. In cell killing experiments, the PA-1 cells were sensitized with the S2 polyclonal antibody. After screening of many monoclonal antibodies, two were found that bound to the PA-I cells and activated C (C241 against CAl9-9 and Ma552 against MUC-1). Unfortunately, the binding of these antibodies to PA-I cells was too weak to lead to efficient C activation. S2-sensitized PA-I cells in suspension were shown to be C treated, as almost 65% of the cells were killed after C activation. Neutralization of CD59 enhanced cell killing to more than 85%. In contrast, PA-1 cells growing in TMSs were C resistant; less than 10% of the cells were killed by C. Blocking of CD59 with biotinylated YTH53.1 reduced the resistance of the TMSs to C-mediated lysis only very moderately. The spheroids remained resistant even when higher concentrations of both biotinylated YTH53.1 and NHS were used (data not shown). An earlier study by Buckman et al (1982) obtained similar results by showing that a monoclonal antibody, Fib-75, activated complement on epithelial tumour cells and killed the cells when they were in suspension but not when they were in large clumps.
The difference in PA-1 sensitivity to C lysis between the two systems could be partly determined by the variable access of the C-activating antibodies to the tumour cells. Spheroid tissue may prevent deeper penetration of C until the most superficial cell layers have become damaged, and even after cell damage a barrier of some degree may remain. When high-affinity antibodies are used they may bind avidly to the outermost surface and do not necessarily penetrate deeper into the TMSs. Despite the fact that antibodies bound to TMSs and activated C, no significant C lysis was observed. Recently, we noticed that DAF expression was inversely correlated with the ovarian tumour cells' vulnerability to C-mediated killing (Bj0rge et al, 1996) . Induced expression of DAF on cells localized at the surface of the TMSs, could also partly explain the increased C resistance of the cells. Other mechanisms, such as rapid depletion of C activity or induced resistance to C attack (Morgan, 1989; Reiter et al, 1992) , may also contribute. Further studies are required to see if killing of tumour cells in spheroids can be enhanced by prolonged or repeated C treatment or by employing the antibody-dependent cellular cytotoxicity (ADCC) effector mechanism to the tumour cell killing. It is anticipated that under in vivo conditions ADCC will play an important role in immune attack against tumour cells.
The approach of using MAbs and the C system as an effector to kill tumour cells may be an attractive adjuvant immunotherapeutic alternative (Chapman et al, 1992; Riethmuller et al, 1993) . Attempts to use unconjugated C-activating MAbs in the therapy of solid tumours have therefore been tried (Houghton et al, 1985; Goodman et al, 1990; Riethmuller et al, 1993; Rubin, 1993) . Although the MAbs bind to the tumour cells in vivo (Houghton et al, 1985; Rubin, 1993) and mediate local C deposition (Houghton et al, 1985) , the therapeutic efficiency is limited (Houghton et al, 1985; Riethmuller and Johnson, 1992; Riethmuller et al, 1993; Rubin, 1993) and correlates negatively with the volume of the tumour mass (Riethmuller et al, 1993) . Barriers for free access of MAbs and C to the tumour cells and the existence of C resistance mechanisms may limit the success rate (Riethmuller et al, 1993) . However, in vitro tests have shown that it is possible to kill tumour cells in suspension using appropriate MAbs and C in combination with targeted neutralization of membrane regulators of complement (Cheung et al, 1988; Bj0rge et al, 1994; Hakulinen and Meri, 1994; Junnikkala et al, 1994; Brasoveanu et al, 1995; Maenpaa et al, 1996) . The in vivo protocols for this type of immunotherapeutic analysis therefore have to be refined for effective destruction of tumour cells in three-dimensional structures.
Ovarian cancer represents a good candidate for MAb tumour therapy (Rubin, 1993) . MAbs can be applied by both the intraperitoneal and intravenous route. If the limitations of MAb penetration and resistance to C can be overconie, the clinical use of MAbs in the management of ovarian cancer could enter a new era. ABBREVIATIONS MAC, membrane attack complex; NHS, normal human serum; TMS, tumour microspheroid
